SLRX
Salarius Pharmaceuticals Inc

12,806
Loading...
Loading...
News
all
press releases
Shareholder Alert: Ademi LLP investigates whether Salarius Pharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders
Ademi LLP is investigating Salarius (NASDAQ: SLRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Decoy Therapeutics. Click here to learn how to join our...
Business Wire·8mo ago
News Placeholder
More News
News Placeholder
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket
Shares of Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) rose sharply in today's pre-market trading following fourth-quarter results. read more...
Benzinga·1y ago
News Placeholder
Dada Nexus, Salarius Pharmaceuticals And 3 Stocks To Watch Heading Into Monday
With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: read more...
Benzinga·1y ago
News Placeholder
12 titoli sanitari in movimento, after-market del 22/03/2024
Titoli in rialzo Le azioni di Salarius Pharmaceuticals (NASDAQ:SLRX) sono cresciute del 33,90% a 0,83 dollari durante la sessione after-market di venerd . Il titolo Masimo (NASDAQ:MASI) ha osservato...
Benzinga·1y ago
News Placeholder
12 acciones de salud en movimiento en la subasta de cierre del 22/03/2024
Acciones al alza Salarius Pharmaceuticals (NASDAQ:SLRX) experimentaron un repunte del 35,29% para establecerse en los 0,84 d lares durante la sesi n del after-market del viernes. Masimo (NASDAQ:MASI...
Benzinga·1y ago
News Placeholder
Salarius Pharmaceuticals GAAP EPS of -$3.84
Salarius Pharmaceuticals GAAP EPS of -$3.84...
SeekingAlpha.com: All News·1y ago
News Placeholder
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Company Implemented Significant...
Globe Newswire·1y ago
News Placeholder
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
Company implementing a series of cost-savings measures designed to extend Salarius' expected cash runway into the first half of 2025 Extended runway supports the generation of additional data from...
Globe Newswire·2y ago
News Placeholder
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders
Expands IP portfolio with composition-of-matter protection into 2039 for novel molecular glues Protein degrader portfolio now includes 17 issued patents across six patent families HOUSTON, Jan...
Globe Newswire·2y ago
News Placeholder
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
Additional Ewing Sarcoma Patient in Company's Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients Treated with Seclidemstat, Topotecan and...
Globe Newswire·2y ago

Latest SLRX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.